Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.

Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829. Abstract Text:

MICs of six oral cephalosporins (cefdinir, cefpodoxime, cefaclor, cefuroxime, cefixime and Ro 40-6890), four quinolones (ciprofloxacin, ofloxacin, OPC-17116 and fleroxacin), desacetylcefotaxime, Ro 23-9424 (a fused combination of fleroxacin + desacetylcefotaxime) and RP 67829 (a benzonaphthyridine) were determined for 49 penicillin-susceptible (S), 38 penicillin-intermediate (I), and 83 penicillin-resistant (R) strains of Streptococcus pneumoniae. All MICs were determined by a standardized agar dilution method utilizing Mueller-Hinton agar supplemented with sheep blood. MIC90s of OPC-17116 and RP 67829 were < or = mg/L, and were unaffected by penicillin-susceptibility. MICs of all beta-lactams increased with increasing penicillin-MICs, with cefdinir, cefpodoxime, cefuroxime and Ro 40-6890 being the most active compounds, followed by cefaclor and cefixime. MIC90s of ciprofloxacin and ofloxacin were 2 mg/L. MIC90s of Ro 23-9424 were lower than those of either parent compound (fleroxacin 8 mg/mL for all three groups; desacetylcefotaxime 0.5 mg/mL [S], 0.5 mg/mL [I], 4 mg/mL [R]; Ro 23-9424 0.125 mg/L [S], 0.25 mg/L [I], 0.5 mg/L [R]). The results indicated that several newly introduced and experimental antimicrobials have potential for the treatment of infections caused by resistant strains of S. pneumoniae.

Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: The Journal of antimicrobial chemotherapy

VOLUME: 31

Page Numbers: 273-80

Journal Abbreviation: J. Antimicrob. Chemother.

ISSN: 0305-7453

DAY: 24

MONTH: Feb

YEAR: 1993

Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7513617

Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829. Keywords Mesh Terms:

KEYWORDS: Streptococcus pneumoniae

MESH TERMS: drug effects

Chemical & Substance for Abstract: Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829. Information

Substance Name: Fleroxacin

Registry Number: 79660-72-3

Grant and Affiliation Information for Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.

AFFILIATION: Department of Pathology (Clinical Microbiology), Hershey Medical Center, Hershey, PA 17033.

Country: ENGLAND

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Antimicrob Chemother

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829 Related Publications

• A direct comparison of research decision-making capacity: Schizophrenia/schizoaffective, medically ill, and non-ill subjects.
• Activity of Meropenem with and without Ciprofloxacin and Colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
• Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis.
• Agnogenic myeloid metaplasia: a case report.
• Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
• Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
• Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.
• Coherent Spin Transport through a 350 Micron Thick Silicon Wafer.
• Commentary: the use of restraint and seclusion in correctional mental health.
• Comparative Antianaerobic Activities of Doripenem Determined by MIC and Time-Kill Analysis.
• Development of autonomy: role of walking onset and its timing.
• Disclosure of information to potential subjects on research recruitment web sites.
• Ethics and forensic psychiatry: translating principles into practice.
• Genetic characterization of erythromycin- and methicillin-resistant community-acquired Staphylococcus aureus isolated from children in Texas.
• Hematopoietic cell transplantation for non-Hodgkin's lymphoma: yesterday, today, and tomorrow.
• Hormone receptors in breast cancer.
• Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.
• In Vitro Activity of DC-159a, a New Broad-Spectrum Fluoroquinolone, Compared with That of Other Agents against Drug-Susceptible and -Resistant Pneumococci.
• In Vitro Capability of Faropenem To Select for Resistant Mutants of Streptococcus pneumoniae and Haemophilus influenzae.
• Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML).
• Law & psychiatry: Death row delusions: when is a prisoner competent to be executed?
• Law & psychiatry: privilege in the federal courts: should there be a "dangerous patient exception"?
• Law & psychiatry: sex offenders in the community: are current approaches counterproductive?
• Molecular characterization of multidrug-resistant Streptococcus pneumoniae isolates in Korea. The Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group.
• Patients' competence to consent to treatment.
• Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500).
• Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
• Retrolental fibroplasia; a disease of the eyes in premature infant; with report of a case.
• Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.
• The voluntary patient--a psychiatrist's perspective.